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Abstract
Introduction: Therapy-related acute myeloid leukemia occurs as a complication of treatment with chemotherapy,
radiotherapy, immunosuppressive agents or exposure to environmental carcinogens.
Case presentation: We report a case of therapy-related acute myeloid leukemia in a 37-year-old Turkish woman in
complete remission from breast cancer. Our patient presented to our facility with fatigue, fever, sore throat,
peripheral lymphadenopathy, and moderate hepatosplenomegaly. On peripheral blood and bone marrow aspirate
smears, monoblasts were present. Immunophenotypic analysis of the bone marrow showed expression of CD11b,
CD13, CD14, CD15, CD33, CD34, CD45 and human leukocyte antigen-DR, findings compatible with the diagnosis of
acute monoblastic leukemia (French-American-British classification M5a). Therapy-related acute myeloid leukemia
developed three years after adjuvant chemotherapy consisting of an alkylating agent, cyclophosphamide and DNA
topoisomerase II inhibitor, doxorubicin and adjuvant radiotherapy. Cytogenetic analysis revealed a 46, XX, deletion
7 (q22q34), deletion 20 (q11.2q13.1) karyotype in five out of 20 metaphases and inversion 16 was detected by
fluorescence in situhybridization. There was no response to chemotherapy (cytarabine and idarubicin, FLAG-IDA
protocol, azacitidine) and our patient died in the 11th month after diagnosis.
Conclusions: The median survival in therapy-related acute myeloid leukemia is shorter compared to de novoacute
myeloid leukemia. Also, the response to therapy is poor. In therapy-related acute myeloid leukemia, complex
karyotypes have been associated with abnormalities of chromosome 5, rather than 7. To the best of our
knowledge, this is the first case of therapy-related acute myeloid leukemia showing the co-presence of deletion 7q,
20q and the inversion 16 signal.
Introduction
Therapy-related acute myeloid leukemias (t-AML) are
long-term adverse consequences in malignant diseases
treated with chemotherapy, radiation therapy or immu-
nosuppressive agents [1]. The commonest subtype of
t-AML develops after exposure to alkylating agents.
Most cases present with monosomy/deletion of chromo-
some 5q and/or monosomy/deletion of 7q [2,3]. The
majority of alkylating agents and radiotherapy treat-
ments damage DNA by methylation [1]. Balanced trans-
locations involving chromosome bands 11q23 and
21q22 may develop following therapy with DNA topoi-
somerase II inhibitors [4]. Inversion 16 (inv(16)) is one
of the less frequent genetic alterations observed after
exposure to DNA topoisomerase II inhibitors [4]. In the
Chicago University series of 386 patients with therapy-
related myelodysplastic syndrome (t-MDS) and t-AML,
only eight (2%) patients had abnormalities of -Y, +11,
del(11q), del(20q), +21 [5]. Qian et al. reported that
complex karyotypes in primary MDS, AML de novo, or
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chromosome 5, rather than chromosome 7 [5]. Here, we
report a case of t-AML developed after adjuvant che-
moradiotherapy for breast cancer. Cytogenetic analysis
revealed abnormalities of both chromosomes 7 and 20
(del(7q) and del(20q)). Fluorescence in situ hybridization
(FISH) analysis revealed the inv(16) signal.
Case presentation
A 37-year-old Turkish woman was examined for a mass
in the upper lateral quadrant of her right breast three
years ago. She had a family history of endometrial carci-
noma. A mammography study revealed a 22 mm nodular
lesion with irregular peripheral borders in the lateral
upper quadrant of her right breast. There were no palp-
able axillary lymph nodes. A 3.2 × 2.2 × 2 cm mass in the
right breast was detected on breast ultrasonography
(USG). An incisional biopsy of the mass led to a diagnosis
of invasive ductal carcinoma and a breast-conserving par-
tial mastectomy of the right breast with axillary dissec-
tion was performed. There were no metastases detected
on abdominal USG, thorax tomography and bone scinti-
graphy. Pathological examination of the operation mate-
rial revealed invasive ductal carcinoma. The tumor was
found to be stage IIA (T2N0M0). Four cycles of AC com-
bination chemotherapy (adriamycin 40 mg/m
2 on day
one and cyclophosphamide 200 mg/m
2/day on days three
to six at 28-day intervals) was given. In addition, adjuvant
radiotherapy (60.4 Gy for 33 days) was performed. There
was no metastasis or recurrence detected in the period
during and after adjuvant treatment. Three years after
chemotherapy, our patient was admitted to our emer-
gency department because of fatigue, fever and sore
throat. On clinical examination, hepatosplenomegaly
(both 2 cm below the costal margins), cervical lymphade-
nopathy and petechiae were noted. Her laboratory test
r e s u l t sw e r ea sf o l l o w s :h e m oglobin 9 g/dL, hematocrit
32%, total leukocytes 343,000 cells/mm
3, platelets 79,000
cells/mm
3, erythrocyte sedimentation rate 51 mm/hour,
lactate dehydrogenase (LDH) 2250 U/L, creatinine 1.3
mg/dL, uric acid 5.5 mg/dL, calcium 8.8 mg/dL, phos-
phorus 3.5 mg/dL and C-reactive protein 21.1 g/L. A per-
ipheral blood smear showed diffuse myeloblasts.
Antibacterial therapy was started, with a diagnosis of
febrile neutropenia. Our patient was referred to our
hematology department. A bone marrow aspirate
revealed a 100% infiltration composed of monoblasts.
A subsequent bone marrow biopsy showed diffuse infil-
tration by leukemic blast cells that were diffusely positive
for CD34, and focally positive for CD33, myeloperoxidase
and lysozyme. Immunophenotypic analysis of the bone
marrow was positive for CD11b, CD13, CD14, CD15,
CD33, CD34, CD45 and human leukocyte antigen
(HLA)-DR. Based on these data, a diagnosis of acute
monoblastic leukemia (French-American-British (FAB)
classification M5a) was made. On cytogenetic analysis of
the bone marrow, five of the examined 20 metaphases
revealed a 46, XX, del(7)(q22q34), del(20)(q11.2q13.1)
karyotype (Figure 1). Karyotypes were coded according to
International Standing Committee on Human Cytoge-
netic Nomenclature (ICSN) guidelines [6]. FISH analysis
of the bone marrow revealed an inv(16) signal. A remis-
sion induction regime including cytarabine 100 mg/m
2
daily on days one to seven and idarubicin 12 mg/m
2 daily
on days one to three was initiated. On the 28th day of
the regimen, no remission was obtained. Therefore, re-
induction therapy with the same regimen was given. On
the 28th day of the re-induction therapy, bone marrow
aspirate revealed 85% monoblasts. Because of refractory
disease, FLAG-IDA chemotherapy, a more aggressive
regimen consisting of a five-day course of 30 mg/m
2 per
day fludarabine, 2 g/m
2 per day cytosine arabinoside,
granulocyte colony-stimulating factor, and a three-day
course of idarubicin 8 mg/m
2 was applied. After 10 days
of persistent fever despite broad-spectrum antibacterial
therapies, empirical antifungal treatment was added.
Thorax tomography revealed bilateral diffuse ground-
glass opacities and bilateral pleural effusions. Serum galac-
tomannan was positive. The final diagnosis was invasive
fungal aspergillosis of the lung. On the 28th day of the
FLAG-IDA protocol, bone marrow aspirate revealed 80%
monoblasts and on cytogenetic analysis of the bone mar-
row; five of the examined 20 metaphases still revealed a
46, XX, del(7)(q22q34), del(20)(q11.2q13.1) karyotype. The
inv(16) signal disappeared on FISH analysis. One schedule
of azacitidine (75 mg/m
2/day subcutaneously for seven
days) and two schedules of azacitidine (100 mg/m
2/day
subcutaneously for seven days) every 28 days were per-
formed. However, no remission was obtained and our
patient died 10 months after diagnosis due to sepsis and
pulmonary failure.
Conclusions
The World Health Organization (WHO) classification of
therapy-related myeloid neoplasms (t-MN) includes t-
AML, t-MDS, or myelodysplastic syndrome/myeloproli-
ferative neoplasms (t-MDS/MPN) that develop secondary
to exposure to cytotoxic agents or radiation [7]. The
median survival is shorter compared to de novoAML,
MDS, or MDS/MPN. Also, the response to therapy is
poor. In our patient’s case, remission was never achieved.
The latency period between first exposure to a cytotoxic
agent and the development of t-MN ranges from one to
10 years. t-MN occurs five to seven years after exposure
to alkylating agents and radiotherapy [8,9]. This period
was one to three years after the use of DNA
Yonal et al. Journal of Medical Case Reports 2012, 6:67
http://www.jmedicalcasereports.com/content/6/1/67
Page 2 of 5topoisomerase II inhibitors [10,11]. Our patient pre-
sented to our facility in a leukemic state three years after
exposure to chemoradiotherapy.
t-MN has been reported after chemotherapy with
alkylating agents and/or topoisomerase inhibitors for the
treatment of Hodgkin’s disease, non-Hodgkin’sl y m -
phoma, acute lymphoblastic leukemia, breast cancer,
ovarian carcinoma, or testicular carcinoma [12-16].
Among solid tumors, breast cancer is the one most
commonly associated with an increased risk of develop-
ment of t-MN.
Taking into consideration the increase in survival and
overall cure rate of patients with cancer, the potential
risk of therapy-associated secondary malignancies is of
growing interest. Nowadays, this issue is becoming parti-
cularly important as a significant number of patients with
breast cancer receive adjuvant chemotherapy following
complete surgical resection. Adjuvant chemotherapy
improves survival among women with high-risk breast
cancers [17]. The late side effects related to chemother-
apy in this particular group of patients need to be clearly
elucidated. Certain cytotoxic drugs increase the risk of
developing a secondary malignancy. Specifically, t-MN
can develop after treatment with alkylating agents and
topoisomerase II reactive drugs. Treatment for breast
cancer is associated with a 1% to 5% lifetime risk of t-
MN. Praga et al. analyzed 9796 patients with breast can-
cer treated in 19 randomized trials. The cumulative
eight-year risk of t-AML was reported as 0.55% [18]. The
risk of t-MN increased with higher cumulative doses of
both alkylating agents and anthracyclines [18]. Martin et
al. reported that younger age at the time of diagnosis,
advanced stage disease with distal involvement and radio-
therapy were significant risk factors for t-MN in patients
with breast cancer [19]. In our patient, who received
standard-dose chemotherapy, the identified risk factors
for t-AML were young age at the time of diagnosis and
radiotherapy.
Alkylating agents have been shown to affect tissue
DNA methylation profile [1]. Radiation is also able to
induce a stable DNA hypomethylation in both target and
bystander tissues. t-MN following ionizing radiations can
be assimilated to leukemias following alkylating agents.
Voso et al. demonstrated the correlation between p15
Figure 1 Karyogram showing deletion 7q and deletion 20q.
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proposing it as a relevant event in alkylating-agent-
induced leukemogenesis [1]. In alkylating-agent-induced
t-MN, 60% to 90% of patients present with monosomy/
deletion of 5q and/or monosomy/deletion of 7q [4]. The
first subgroup includes cases of t-MN with monosomy/
deletion of 5q, with or without abnormalities of chromo-
some 7. Such cases often present monosomy of chromo-
some 17 or deletion or loss of 17p, duplication or
amplification of chromosome band 11q23, and a complex
karyotype with many unidentified abnormalities. The sec-
ond subgroup of t-MN includes cases with monosomy/
deletion of 7q, but normal chromosome 5. Qian et al.
reported cytogenetic pattern of 3444 patients with pri-
mary MDS, AML de novo, or t-MN. They found that
16% of patients had del(5q), and 17.3% had del(7q). Com-
plex karyotypes were associated with abnormalities of
chromosome 5, rather than 7. Recurring abnormalities
observed at a high frequency (> 20%) in patients with del
(5q) included +8, and loss of 13q, 16q, 17p (40% of
cases), chromosome 18, and 20q [5]. In our patient, how-
ever, other genetic abnormalities (del 20q and the inv
(16)) were present in addition to the chromosomal
abnormality on chromosome 7.
The latency between the alkylating agents and t-MN is
between five and seven years. This group often exhibits
a M1 or M2 phenotype (FAB classification). Generally,
overt leukemia develops following a dysplastic phase.
t-MN related to alkylating agents typically has a poor
prognosis [4].
Chromosomal breakage induced by DNA topoisomerase
II inhibitors is responsible for its antineoplastic and leuke-
mogenic effects, and this breakage resolved by chromoso-
mal translocation is the cause of the leukemic
transformation [4]. t-MN after DNA topoisomerase II
inhibitors typically has a short latency time, ranging
between one and three years from primary treatment
[4,15]. Among the genetic derangements associated with
DNA topoisomerase II inhibitors, translocations at the
long arm of chromosome 11 (11q23) are the most
followed by t(8;21), t(3;21), t(16;21), t(17;21), inv(16),
t(8;16) and t(9;22) [4]. DNA topoisomerase II inhibitor-
related t-AML most commonly presents with M4 or M5
morphological type and is not associated with MDS. We
present a case with M5 morphological type. Pedersen-
Bjergaard et al. were the first to report the presence of inv
(16)(p13q22) as a single chromosomal abnormality in t-
AML treated with radiotherapy and subsequently with
MOPP (nitrogen mustard, vincristine, procarbazine, and
prednisone) in a patient with Hodgkin’s disease [15]. In
our patient with AC chemotherapy-related AML, inv(16)
(p13q22) was one of the three chromosomal abnormalities
observed.
In the National Surgical Adjuvant Breast and Bowel Pro-
ject (NSABP) B25 trial of adjuvant AC chemotherapy for
breast cancer, six out of 2534 cases in the high-dose cyclo-
phosphamide/high-dose doxorubicin treatment arm devel-
oped M4 or M5 AML, with three patients exhibiting
11q23 abnormalities. Topoisomerase II was accounted for
development of leukemia in these patients. Ten other
patients developed AML or MDS, with three patients exhi-
biting M1 or M2 morphology and five patients showing
typical alkylating-agent-induced abnormalities of chromo-
somes 5 or 7 [20]. To the best of our knowledge, our
patient’s case is the first case of t-AML showing M5 mor-
phology with del 7q, 20q and the inv(16) signal developed
three years after chemoradiotherapy for breast cancer.
With recent developments and improved cure rates in
cancer therapy, t-MN is an increasingly recognized
obstacle. Patients must be informed about the potential
risk of developing t-MN following chemotherapy.
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